Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Chugai
Chugai
Roche autoimmune disease drug disappoints in closely watched trial
BioPharma Dive
Thu, 03/21/24 - 06:36 pm
Roche
Chugai
clinical trials
myasthenia gravis
Enspryng
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag
BioSpace
Thu, 09/15/22 - 10:14 am
hemophilia
gene therapy
ICER
Biomarin
Chugai
Roche
CSL Behring
Roche's Chugai pays Halozyme $25M to access subcutaneous delivery tech
Fierce Biotech
Tue, 03/29/22 - 10:36 am
Roche
Chugai
drug delivery
subcutaneous drug delivery
Haolzyme Therapeutics
Enhanze
After Alexion buyout, AstraZeneca pays Roche $775M to settle Ultomiris patent brawl
Fierce Pharma
Thu, 03/17/22 - 10:38 am
AstraZeneca
Roche
Chugai
Ultomiris
patents
Roche and AstraZeneca settle years long patent battle over Ultomiris — report
Endpoints
Sun, 02/20/22 - 11:48 am
Roche
Chugai
AstraZeneca
Alexion
patents
Ultomiris
Soliris
7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
Thu, 01/13/22 - 07:31 am
FDA
adagrasib
donanemab
faricimab
lecanemab
tezepelumab
tirzepatide
vutrisiran
Eli Lilly
Mirati Therapeutics
Roche
Chugai
Eisai
Biogen
AstraZeneca
Amgen
Alnylam
Chugai’s Enspryng receives regulatory approval from FDA for neuromyelitis optica spectrum disorder
Pharmaceutical Business Review
Mon, 08/17/20 - 10:31 am
Chugai
FDA
Enspryng
NMOSD
Verastem pens KRAS-focused drug licensing deal with Chugai
Fierce Biotech
Wed, 01/8/20 - 10:34 am
Verastem
KRAS
cancer
Chugai
Roche's Chugai claims Alexion co-opted its patented tech in building Ultomiris
Fierce Pharma
Wed, 11/13/19 - 11:24 pm
Alexion
Chugai
Roche
Ultomiris
patents
Roche's Chugai to set up new $1B+ lab in Yokohama, consolidating R&D
Endpoints
Wed, 05/22/19 - 10:03 am
Chugai
Roche
Japan
R&D
Lilly Licenses Chugai Pharma's Oral Diabetes Drug for $50 Million Upfront
BioSpace
Thu, 09/27/18 - 11:53 am
Eli Lilly
Chugai
OWL833
type 2 diabetes
Hey, wait a second. What about Roche’s PhIII hemophilia A drug?
Endpoints
Fri, 07/29/16 - 11:24 am
Roche
hemophilia A
Chugai
emicizumab
ACE910
Galderma licenses PhII atopic dermatitis drug from Roche’s Chugai
Fierce Biotech
Fri, 07/22/16 - 11:47 am
Galderms
atopic dermatitis
Roche
Chugai
nemolizumab
Patent Claims To Xtandi Seem Weak
Seeking Alpha
Tue, 08/11/15 - 11:20 am
patents
Xtandi
Chugai
Roche
Chugai Pharma Appears To Own U.S., Japan And EU Patent Rights To Medivation's Xtandi
Seeking Alpha
Tue, 05/12/15 - 04:29 pm
Chugai
Medivation
Xtandi
patents
Japan
Europe
As PhII data looms, Chugai inks a $205M stem cell deal with Athersys
Fierce Biotech
Mon, 03/2/15 - 09:48 pm
Chugai
stem cells
Athersys
Chugai pours $374M into its Singapore R&D shop
Fierce Biotech
Mon, 02/2/15 - 05:55 pm
Chugai
Singapore
R&D
Chugai Pharmabody Research
Roche Sees ‘No Urgency’ to Buy Rest of Chugai, CFO Says
Bloomberg
Wed, 01/14/15 - 10:14 am
Roche
Chugai
M&A
Roche Said to Have Decided Against Bid for Rest of Chugai
Bloomberg
Mon, 08/25/14 - 09:10 am
Roche
Chugai
M&A
InterMune
Pages
1
2
next ›
last »